People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Schrodinger, Inc. | — | Biotechnology | Series D+ | $159.8M | $4.4B | 2018 |
| Superluminal Medicines, Inc. | — | Biotechnology | Series B | $50.7M | $22.1M | 2023 |
CONY D'CRUZ at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside CONY D'CRUZ on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Dylan Morris | 1 | 8 |
| Timothy Wright | 1 | 7 |
| Michael Lynton | 1 | 6 |
| Ramy Farid | 1 | 5 |
| DIAMANTIS XYLAS | 1 | 2 |
| CATHERINE RIESEN | 1 | 2 |
| CRAIG RANDALL | 1 | 1 |
| Joel Lebowitz | 1 | 1 |
| Rosana Kapeller-Liebermann | 1 | 1 |
| Yvonne Tran | 1 | 1 |
| Wayne Guida | 1 | 1 |
| Richard Friesner | 1 | 1 |
| Murco Ringnalda | 1 | 1 |
| Charles Ardai | 1 | 1 |
| Louis Salkind | 1 | 1 |
| Joshua Distler | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.